Last edition
News about "Shreeram Aradhye"
Novartis Updates Phase 3 HARBOR Study of Del-desiran for DM1
Novartis reports del-desiran showed clinical activity in secondary endpoints and exploratory analyses in the phase 3 HARBOR study for DM1.
Shreeram Aradhye | 09/09/2026 | By News Bureau | 125
Novartis Remibrutinib Reduces Relapse Rates in Phase 3 RMS Trials
Novartis’ remibrutinib significantly reduces annualised relapse rates versus teriflunomide in phase 3 RMS trials, with a favorable safety profile and no liver safety signal.
Shreeram Aradhye | 02/09/2026 | By News Bureau
Novartis Signs Deal with Synnovation Therapeutics to Explore Next-Gen Breast Cancer Treatment
Novartis has signed a deal with Synnovation Therapeutics to advance SNV4818, a next-generation PI3Kα inhibitor in phase-I/II trials, targeting HR+/HER2- breast cancer patients with PIK3CA mutations, addressing a significant unmet need.
Shreeram Aradhye | 20/03/2026 | By News Bureau | 145
Novartis Reports Promising Results for New Anti-Malaria Drug to Tackle Growing Resistance
Novartis’ Phase III trial of KLU156 (GanLum) met its primary endpoint, showing a 97.4 percent PCR-corrected cure rate comparable to Coartem. If approved, GanLum would mark the first major malaria treatment breakthrough in over two decades, targeting drug-resistant parasites.
Shreeram Aradhye | 13/11/2025 | By Dineshwori | 286
Novartis to Acquire Tourmaline Bio for USD 48 per share
Novartis to acquire Tourmaline Bio in a USD 1.4 billion deal, gaining rights to pacibekitug—an anti-IL-6 antibody with potential in cardiovascular disease; transaction expected to close in Q4 2025.
Shreeram Aradhye | 09/09/2025 | By Dineshwori | 359
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy